Výsledky vyhledávání

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

Publikováno v: Cancer Res

The RAS family of small GTPases represents the most commonly activated oncogenes in human cancers. To better understand the prevalence of somatic RAS mutations and the compendium of genes that are coaltered in RAS-mutant tumors, we analyzed targeted

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54809b35bdad1607cdd63cfd001a916e
https://doi.org/10.1158/0008-5472.can-22-1731

Zobrazit plný text záznamu

Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::860e1fc094747e64ca35b9eb6afb0c6a
https://doi.org/10.1158/0008-5472.c.6514292.v1

Zobrazit plný text záznamu

Supplementary Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

Supplementary Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0144725fc4b6c790ec3431ec0bc92d36
https://doi.org/10.1158/0008-5472.22433051.v1

Zobrazit plný text záznamu

Implementing Real-World RECIST-based Tumor Response Assessment in Patients With Metastatic Non-small Cell Lung Cancer

Autor: Monika A. Izano, Nguyet Tran, Alan Fu, Liz Toland, Danny Idryo, Ryan Hilbelink, Huakang Tu, Hil Hsu, Chris Sommers, Matthew Rioth, Thomas Brown

Publikováno v: Clinical Lung Cancer. 23:191-194

To accelerate drug approvals while maintaining scientific rigor in the evaluation of a therapeutic's efficacy and safety, the United States Food and Drug Administration now considers real-world data (RWD) to support New Drug Applications and expanded

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8f6dfcad5547a30f17f2ef5b6993d2c
https://doi.org/10.1016/j.cllc.2022.01.002

Zobrazit plný text záznamu

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer

Autor: Marwan Fakih, Huakang Tu, Hil Hsu, Shivani Aggarwal, Emily Chan, Marko Rehn, Victoria Chia, Scott Kopetz

Publikováno v: The Oncologist. 27:663-674

Background The KRAS p.G12C mutation has recently become an actionable drug target. To further understand KRAS p.G12C disease, we describe clinicopathologic characteristics, treatment patterns, overall survival (OS), and real-world progression-free su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974d01891eec7f4bfad7423720f7329b
https://doi.org/10.1093/oncolo/oyac077

Zobrazit plný text záznamu

Real-world outcomes in patients with KRAS G12C–mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond

Autor: Jhanelle E. Gray, Hil Hsu, Diana Younan, Gaurav Suri, Victoria Chia, Alexander Spira, Melissa Johnson

Publikováno v: Lung Cancer. :107260

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fa3ca5ac2434e538fb9d9be7fdb55cbe
https://doi.org/10.1016/j.lungcan.2023.107260

Zobrazit plný text záznamu

Real-world outcomes in patients with KRAS p.G12C mutant advanced non-small cell lung cancer (aNSCLC) treated with docetaxel in second-line or beyond (2L+)

Autor: Hil Hsu, Diana Younan, Gaurav Suri, Victoria M. Chia

Publikováno v: Journal of Clinical Oncology. 40:e21048-e21048

e21048 Background: KRAS p.G12C mutation accounts for ̃13% of non-squamous NSCLCs and recently became a druggable target. Prior standard of care (SOC) treatment options have been limited to checkpoint inhibitors and chemotherapies as a monotherapy or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::136994965d96592529f4e3026865b925
https://doi.org/10.1200/jco.2022.40.16_suppl.e21048

Zobrazit plný text záznamu

Abstract 102: Clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS p.G12C-mutated metastatic non-small cell lung cancer (NSCLC) in the AACR Project GENIE database

Autor: Jacklynn Egger, Biagio Ricciuti, Gataree Ngarmchamnanrith, Mark M. Awad, G. J. Riely, Victoria M. Chia, Shivani Aggarwal, Xuena Wang, Hil Hsu, Marilyn E. Holt, Valsamo Anagnostou, Chenguang Wang, Robert B. Scharpf, Hira Rizvi, Michele LeNoue-Newton, Huakang Tu, Christine M. Lovly, Jocelyn A. Lee

Publikováno v: Cancer Research. 81:102-102

Introduction: Mutations in the RAS family of proto-oncogenes are frequently found in NSCLC, with KRAS being the most prevalent mutated isoform. Of KRAS mutations, the most common is KRAS G12C, representing ~40% of KRAS mutations and occurring in ~13%

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fc28575c1acc0788f83965789c1090d9
https://doi.org/10.1158/1538-7445.am2021-102

Zobrazit plný text záznamu

Feasibility of RECIST-based real-world tumor response assessment in metastatic non-small cell lung cancer patients

Autor: Chris Sommers, Nguyet Tran, Huakang Tu, Hil Hsu, Alan Fu, Liz Toland, Thomas D. Brown, Ryan Hilbelink, Matthew J. Rioth, Monika A Izano

Publikováno v: Journal of Clinical Oncology. 39:e21121-e21121

e21121 Background: Treatment response to anti-cancer therapies for advanced lung cancer is usually assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST), which is not generally applied in real-world settings. With real-world

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db1ab170eed5ef2c7bebe7036b8bf077
https://doi.org/10.1200/jco.2021.39.15_suppl.e21121

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání